Secukinumab for Treatment of Atopic Dermatitis

NCT02594098 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Secukinumab
DRUG: Placebo

Sponsor

Icahn School of Medicine at Mount Sinai

Collaborators

[object Object]